{"id":"NCT01047345","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)","officialTitle":"A Phase III, Randomized, International, Placebo-Controlled, Double-Blind Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given to Females 12-26 Years of Age Who Have Previously Received GARDASIL™","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-02-24","primaryCompletion":"2011-06-10","completion":"2015-11-28","firstPosted":"2010-01-12","resultsPosted":"2014-12-22","lastUpdate":"2018-11-27"},"enrollment":924,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Cervical Cancers","Vulvar Cancers","Vaginal Cancers","Genital Warts"],"interventions":[{"type":"BIOLOGICAL","name":"V503","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo to V503","otherNames":[]}],"arms":[{"label":"9vHPV Vaccine","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will evaluate whether V503 (9vHPV vaccine), is well tolerated in girls and women between 12 and 26 years old who have previously been vaccinated with GARDASIL™. Participants will receive vaccination with 9vHPV vaccine or placebo on Day 1, Month 2, and Month 6 of the Base Study. Participants who receive placebo in the Base Study will be eligible to receive vaccination with 9vHPV vaccine on Day 1, Month 2, and Month 6 of the Extension Study.","primaryOutcome":{"measure":"Percentage of Participants Who Experience an Injection-site Adverse Event (AE) - Base Study","timeFrame":"up to 5 days after any vaccination - Base Study","effectByArm":[{"arm":"9vHPV Vaccine - Base Study","deltaMin":91.1,"sd":null},{"arm":"Placebo - Base Study","deltaMin":43.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":11,"exclusionCount":10},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["26411885","27422279","29211620"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":608},"commonTop":["Injection site pain","Injection site swelling","Injection site erythema","Headache","Nasopharyngitis"]}}